Loading...

Jushi Holdings Inc.

JUSHFPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.68
$0.02(2.43%)

Jushi Holdings Inc. (JUSHF) Financial Performance & Income Statement Overview

Explore the financials of Jushi Holdings Inc. (JUSHF), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
-29.19%
29.19%
Operating Income Growth
39.37%
39.37%
Net Income Growth
44.49%
44.49%
Operating Cash Flow Growth
581.64%
581.64%
Operating Margin
0.03%
0.03%
Gross Margin
42.17%
42.17%
Net Profit Margin
-22.61%
22.61%
ROE
99.40%
99.40%
ROIC
0.02%
0.02%

Jushi Holdings Inc. (JUSHF) Income Statement & Financial Overview

Review Jushi Holdings Inc. JUSHF income statement with detailed quarterly and annual figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$63.85M$65.86M$61.61M$64.59M
Cost of Revenue$38.07M$40.45M$33.61M$32.03M
Gross Profit$25.77M$25.41M$28.00M$32.57M
Gross Profit Ratio$0.40$0.39$0.45$0.50
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$33.16M$54.50M$32.23M$27.82M
Operating Expenses$27.65M$27.25M$27.82M$24.16M
Total Costs & Expenses$94.56M$67.70M$83.07M$56.19M
Interest Income$175049.00$78000.00$128000.00$337962.00
Interest Expense$10.12M$9.51M$9.51M$12.75M
Depreciation & Amortization$8.04M$7.91M$7.77M$7.38M
EBITDA$10.12M$8.54M$10.23M$24.09M
EBITDA Ratio$0.16$0.13$0.17$0.37
Operating Income-$1.87M-$1.84M$180000.00$8.40M
Operating Income Ratio-$0.03-$0.03$0.003$0.13
Other Income/Expenses (Net)-$6.17M-$7.04M-$7.23M-$1.01M
Income Before Tax-$8.04M-$8.88M-$7.05M$7.39M
Income Before Tax Ratio-$0.13-$0.13-$0.11$0.11
Income Tax Expense$8.98M$3.59M$8.96M$9.33M
Net Income-$17.02M-$12.47M-$16.02M-$1.94M
Net Income Ratio-$0.27-$0.19-$0.26-$0.03
EPS-$0.09-$0.06-$0.08-$0.01
Diluted EPS-$0.09-$0.06-$0.08-$0.01
Weighted Avg Shares Outstanding$195.20M$193.80M$193.80M$193.80M
Weighted Avg Shares Outstanding (Diluted)$195.20M$195.14M$195.14M$195.14M

Financial performance has remained strong, with revenue growing from $64.59M in Q2 2024 to $63.85M in Q1 2025. Gross profit continued to perform well, with margins at 40% in the latest quarter. Operating income reached -$1.87M in Q1 2025, holding a steady -3% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $10.12M. Net income dropped to -$17.02M, keeping EPS at -$0.09. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;